HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.

AbstractBACKGROUND:
Patients with early onset multiple sclerosis may develop disability at a younger age than adults. There are several reports about safety of beta interferons in childhood and juvenile MS with different doses.
OBJECTIVES:
To determine safety and efficacy of substandard dose of intramuscular interferon beta-1a in a prospective randomized trial in patients with multiple sclerosis under the age of 16.
METHODS:
Sixteen patients were divided into two groups randomly. The first group was treated with intramuscular interferon beta-1a 15 micrograms once a week and the second group received no disease-modifying therapy.
RESULTS:
The patients were followed for four years. There was no significant side effect and none of the treated patients discontinued the drug. There were significant differences between two groups regarding relapse rates (p = 0.04), disability progression (p = 0.01), and new T2 lesions (p = 0.006).
CONCLUSION:
Treatment with interferon beta-1a is well tolerated for a long period of time and may be effective in substandard doses in early onset multiple sclerosis.
AuthorsH Pakdaman, A Fallah, M A Sahraian, R Pakdaman, A Meysamie
JournalNeuropediatrics (Neuropediatrics) Vol. 37 Issue 4 Pg. 257-60 (Aug 2006) ISSN: 0174-304X [Print] Germany
PMID17177154 (Publication Type: Evaluation Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Immunologic Factors
  • Interferon-beta
Topics
  • Adolescent
  • Child
  • Disability Evaluation
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Follow-Up Studies
  • Humans
  • Immunologic Factors (therapeutic use)
  • Injections, Intramuscular (methods)
  • Interferon-beta (therapeutic use)
  • Multiple Sclerosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: